(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...

Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.

The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...

Pfizer Inc. has announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...

Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice.

Bladder cancer is among the top 10 most common cancer types in the world, with approximately 573,000 new cases annually. Men ...

Developed by Professor Guillermo Ameer, the material improves bladder tissue regeneration and overall function better than ...

A team of Northwestern scientists has developed an electroactive "scaffolding" material that improves bladder tissue ...

Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in ...